Search Within

Carl Ola Landgren

Formats
  1. Meeting Abstract (155)
  2. Journal Article (151)
  3. Review (14)
  4. Research Letter (7)
  5. Book Section (3)
  6. Correspondence (2)
  7. Guidelines (2)
  8. Conference Paper (1)
  9. Editorial (1)
Groups
  1. Center for Hematologic Malignancies (336)
  2. Department of Medicine (336)
  3. Hematologic Malignancies Research (336)
  4. Hematologic Malignancies, Division of (336)
  5. Myeloma (336)
  6. Survivorship Research (132)

More Groups

People
  1. Neha Korde (106)
  2. Sham Mailankody (91)
  3. Alexander Lesokhin (83)
  4. Malin Hultcrantz (81)
  5. Hani Hassoun (77)
  6. Sergio Giralt (73)

More People

Years
  1. 2023 (2)
  2. 2022 (4)
  3. 2021 (21)
  4. 2020 (52)
  5. 2019 (56)
  6. 2018 (51)

More Years

Publications
  1. Blood (102)
  2. Haematologica (25)
  3. Clinical Lymphoma, Myeloma and Leukemia (21)
  4. Leukemia and Lymphoma (16)
  5. Biology of Blood and Marrow Transplantation (13)
  6. Blood Cancer Journal (10)

More Publications

Publishers
  1. American Society of Hematology (109)
  2. Elsevier Inc. (45)
  3. Nature Publishing Group (29)
  4. Ferrata Storti Foundation (25)
  5. Taylor & Francis Group (17)
  6. American Association for Cancer Research (15)

More Publishers

Results (336)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Early life dietary pattern and risk of monoclonal gammopathy of undetermined significance
    Meeting Abstract

    Thordardottir, M.; Lindqvist, E. K.; Birgisdottir, B. E.; Steingrimsdottir, L.; Eiriksdottir, G.; Harris, T. B.; Landgren, O.; Gudnason, V.; Torfadottir, J. E.; Kristinsson, S. Y.
    European Journal of Public Health (2017)

    Fulltext@MSK | Save
  • The impact of prior malignancies on second malignancies and survival in MM patients: A population-based study
    Journal Article

    Jonsdottir, G.; Lund, S. H.; Bjorkholm, M.; Turesson, I.; Hultcrantz, M.; Porwit, A.; Jethava, Y. S.; Landgren, O.; Kristinsson, S. Y.
    Blood Advances (2017)

    Fulltext@MSK | Save
  • Serum protein markers of clonal heterogeneity in myeloma
    Journal Article

    Landgren, O.
    The Lancet Haematology (2017)

    Fulltext@MSK | Save
  • Shall we treat smoldering multiple myeloma in the near future?
    Journal Article

    Landgren, O.
    Hematology-American Society of Hematology Education Program (2017)

    Fulltext@MSK | Save
  • Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: A population-based study
    Journal Article

    Thordardottir, M.; Lindqvist, E. K.; Lund, S. H.; Costello, R.; Burton, D.; Korde, N.; Mailankody, S.; Eiriksdottir, G.; Launer, L. J.; Gudnason, V.; more...
    Blood Advances (2017)

    Fulltext@MSK | Save
  • Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12 372 individuals 10-49 years old: A population-based study from the National Health and Nutrition Examination Survey
    Journal Article

    Landgren, O.; Graubard, B. I.; Kumar, S.; Kyle, R. A.; Katzmann, J. A.; Murata, K.; Costello, R.; Dispenzieri, A.; Caporaso, N.; Mailankody, S.; more...
    Blood Cancer Journal (2017)

    Fulltext@MSK | Save
  • Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma
    Journal Article

    Mailankody, S.; Kazandjian, D.; Korde, N.; Roschewski, M.; Manasanch, E.; Bhutani, M.; Tageja, N.; Kwok, M.; Zhang, Y.; Zingone, A.; more...
    Blood Advances (2017)

    Fulltext@MSK | Save
  • Racial/ethnic disparities: Need more work!
    Journal Article

    Landgren, O.
    Blood (2017)

    Fulltext@MSK | Save
  • Galinpepimut-S, a WT1-targeting immuno-oncology treatment, induces specific, robust and durable immune responses (IRs) in patients (Pts) with high-risk (HR) multiple myeloma (MM)
    Meeting Abstract

    Koehne, G.; Devlin, S.; Korde, N.; Mailankody, S.; Heather, L.; Hassoun, H.; Lesokhin, A.; Lendvai, N.; Chung, D.; Sarlis, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2017)

    Fulltext@MSK | Save
  • Cooperative targets of combined mTOR/HDAC inhibition promote MYC degradation
    Journal Article

    Simmons, J. K.; Michalowski, A. M.; Gamache, B. J.; DuBois, W.; Patel, J.; Zhang, K.; Gary, J.; Zhang, S.; Gaikwad, S.; Connors, D.; more...
    Molecular Cancer Therapeutics (2017)

    Fulltext@MSK | Save